Cardiovascular

FDA warns of potentially fatal arrhythmias with azithromycin

On March 12, 2013, the U.S. Food and Drug Administration (FDA) strengthened the warning for QT interval prolongation and torsades de pointes, a potentially fatal heart rhythm, associated with azithromycin (Zithromax or Zmax). Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares